Respiratory syncytial virus is the second most common cause of infant mortality and a major
cause of morbidity and mortality in older adults (aged> 60 years). Efforts to develop a …

Aims To capture the economic and healthcare resource utilization (HCRU) burden in older
adults due to respiratory syncytial virus (RSV) infection. Methods An electronic literature …

Two respiratory syncytial virus (RSV) vaccines (AREXVY® and ABRYSVO®) were recently
approved for older adults in the US. This study aimed to evaluate the cost-effectiveness of …

Background Respiratory syncytial virus (RSV) and influenza virus infections result in a
considerable mortality and morbidity among the aging population globally. Influenza …

Introduction Asthma imposes a crucial economic burden on health systems, especially with
the incorporation of new drugs. Recently, mepolizumab has been approved to prevent …

Respiratory syncytial virus (RSV) is a leading cause of acute respiratory infection (ARI) in
older adults. This study used a static, cohort-based decision-tree model to estimate the …

Vaccines | Free Full-Text | Comment on Postma et al. Predicted Public Health and Economic
Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults …

Background: We aimed to identify influential drivers of the cost-effectiveness of older adult
respiratory syncytial virus (RSV) vaccination in Denmark, Finland, the Netherlands and …

Introduction Among older adults, lower respiratory tract infection (LRTI) caused by
respiratory syncytial virus (RSV) is common. We evaluated the cost-effectiveness of bivalent …

Background/Objectives: To evaluate the health benefits, costs, and cost-effectiveness of
vaccination with bivalent respiratory syncytial virus stabilized prefusion F vaccine (RSVpreF) …